TARA BARTO to Chloride Channel Agonists
This is a "connection" page, showing publications TARA BARTO has written about Chloride Channel Agonists.
Connection Strength
0.185
-
A phase 3, randomized, double-blind, parallel-group study to evaluate tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating mutation. J Cyst Fibros. 2021 03; 20(2):234-242.
Score: 0.185